The purpose of this research is to see if a radioactive tracer called (21-[18F]fluoro-16α,17α-[(R)-1'-α- furylmethylidene)dioxyl]-19-norpregn-4-ene-3,20 dione) (also referred to as 18F-FFNP) with positron emission tomography (PET) scanning can provide more information about your response to endocrine therapy when it is combined with Abemaciclib, a member of the class of medications known as CDK4/CDK6 inhibitors.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Jorge Oldan
Radiology - Research
Clinical or Medical
Interventional
Cancer (Breast)
24-2640
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
